Shots: Cardiff University will receive milestone payments that advance from the discovery collaboration into clinical development and royalty payments on sales of any products that reach the market. Ervaxx will […]readmore
Tags : Targeting
Shots: The P-I dose-escalation study will assess the safety, tolerability, and preliminary efficacy of DS-1055 in adult patients with r/r advanced or metastatic head and neck, gastric and esophageal cancers, […]readmore
Shots: Scenic to receive ~$375M that includes up front, milestones along with royalties on sales of therapies emerges from the collaboration and will receive additional target fees for the therapies […]readmore
Shots: Wigen to transfer its 50% interest in four drugs WJ1024/WJ1075, WJ05129, APL1898, and WJ13404 to Junshi. Wigen to receive $5.3M up front, $64.3M as milestones, and 50% on the […]readmore
Shots: Kite enters into a two-year research collaboration and license agreement with HiFiBiO to discover novel targets and Abs against AML HiFiBiO will receive an up front and will utilize […]readmore
Shots: Evotec to receive $179M/ product as upfront, research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and […]readmore
Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission […]readmore
Shots: Sosei to receive ~$32M as upfront and ~$377M as option fees, development, and commercial milestones along with royalties on global sales of therapies. AbbVie to get an option to […]readmore
Shots: Yumanity will receive $500M upfront and milestones along with royalties on net sales of therapies, in exchange Merck to get an exclusive right to two novels Yumanity’s pipeline programs […]readmore
Shots: Sorrento to get access to plasma containing anti-COVID-19 Abs for identifying and produce mAbs with neutralizing activity against SARS-CoV-2. The company expects to commence the P-I study of triple […]readmore